About RSF Bio

RSF Bio Inc has developed Ataciguat, a first-in-class treatment for calcific aortic valve stenosis (CAVS).

CAVS is the most common valvular disease in the Western world. There are no therapies on the market; surgical valve replacement remained the only viable option – until now.

In 2019, the overall valve market size was $7.5B with a CAGR of 13.2% through 2030. RSF Bio’s technology was developed by Sanofi and Mayo Clinic, the two global leading experts in cardio-pulmonary diseases.

Phases I and II were funded using $65M in non-dilutive grants. Proceeds will fund Phase III; RSF Bio expects an IPO within 18 months with a value between $300-$400M.

$50M is available in Series A, backed by Mayo Ventures. Pre-money is $125M. Minimum check size is $500k.